Antithesis raises $47M to launch an automated testing platform for software

Software testing is hard. Even with the right talent in place, it doesn’t always go as planned — particularly when executed at scale. In a 2020 survey from Electric Cloud, 58% of developers blamed software bugs on test infrastructure and process issues — not design defects.

The market for software testing solutions is quite massive, unsurprisingly, with one estimate pegging it at $55.98 billion. There’s plenty of vendors in the space, from startups like Qase, EvaluAgent and Codegen to incumbents like Azure and AWS.

But a new entrant, Antithesis, thinks it can make a splash.

Antithesis, which emerged from stealth today, was founded by the team behind FoundationDB, the distributed database platform, which Apple quietly acquired in 2015. Following the Apple acquisition, the FoundationDB team dispersed to pursue other Big Tech company jobs, but eventually arrived at the same conclusion: Even sophisticated organizations lacked the software testing tools they needed to be more efficient.

“So, five years ago, a number of us got back together to build Antithesis,” Will Wilson, the co-founder and CEO of Antithesis, told TechCrunch in an email interview. “We took the rigorous testing approach of FoundationDB, matured it, and, after years of operating in stealth, made it the only commercially available system of its kind for general software testing.”

Antithesis’ product continuously scans the newest version of software under development for bugs inside a separate-from-production, simulated environment (complete with virtual hardware, service and networking components), reproducing and providing debugging information for bugs it finds. This approach eliminates the need for developers to manually write their own tests, Wilson claims, which is typically a time-consuming and fraught process.

Antithesis runs software under a range of conditions and predefined properties to report any unintended behavior. When it notices interesting behavior, Antithesis makes a copy of the system state and explores possible outcomes from that point — “more intensely” exploring paths that produce abnormal logs.

“Autonomous testing is an important application [that can make] developers more productive,” Wilson said. “[It] gives engineers almost half their time back that they would’ve spent on bug-related issues and allows them to develop with confidence.”

That’s assuming Antithesis’ tech works as advertised. Investors seem enthusiastic about it in any case — Antithesis today closed a $47 million seed round from Amplify Partners, Tamarack Global, First In Ventures and angel investors, including Howard Lerman, the founder of Yext and Roam.

The round — unusually large for a seed — values Antithesis at $215 million, Reuters first reported and a source familiar with the matter confirmed to TechCrunch.

“A group of existing investors were very excited by our progress and came to us with a proposal to invest more on friendly terms,” Wilson said. “We jumped at the opportunity to keep working with people we trusted and to avoid a big fundraising roadshow with its attendant distractions.”

Virginia-based Antithesis is already working with customers, including Palantir, Ethereum and MongoDB and other unnamed “large enterprises,” as well as startups. But the funding will enable it to grow that base, Wilson says, by expanding Antithesis’ sales and marketing teams, growing engineering and research efforts and supporting ongoing feature and product development.

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
Intel tips plans for a Bitcoin mining ‘Bonanza’ chip thumbnail

Intel tips plans for a Bitcoin mining ‘Bonanza’ chip

Metamorworks/Nature/Getty Images Intel has signaled that the next generation of Bitcoin mining rigs may ship with “Intel Inside” stickers, as the company has announced plans to at least discuss a “Bonanza Mine” chip for mining Bitcoin at an upcoming conference. The upcoming program (PDF link) for the International Solid-State Circuits Conference includes a listing for…
Read More
Merck reveals trial of Molnupiravir pill to treat COVID-19 reduces risk of hospitalization  and death by up to 50% thumbnail

Merck reveals trial of Molnupiravir pill to treat COVID-19 reduces risk of hospitalization and death by up to 50%

บริษัท Merck ผู้ผลิตยาจากสหรัฐอเมริกา ได้เผยแพร่ผลการทดลอง “ยาเม็ดต้านไวรัส” ที่ชื่อว่า Molnupiravir ในระยะที่ 3 โดยที่ Molnupiravir เป็นตัยยาเพื่อรักษา COVID-19 ที่บริษัทพัฒนาร่วมกับ Ridgeback Biotherapeuticsผลปรากฏว่า ยาเม็ด Molnupiravir สามารถลดอาการป่วยที่ต้องเข้าโรงพยาบาลและเสียชีวิตได้ ได้ถึง 50% ในผู้ติดเชื้อที่มีอาการเล็กน้อยถึงปานกลาง ที่สำคัญ ตัวยายังมีประสิทธิภาพในการต้าน COVID-19 ทุกสายพันธุ์ รวมถึงสายพันธุ์ Delta ด้วยโดย Merck ทำการทดลองในกลุ่มตัวอย่างที่เป็นผู้ใหญ่ที่ติดเชื้อ COVID-19 ที่มีอาการเล็กน้อยถึงปานกลาง จำนวน 775 คน ที่จัดอยู่ในกลุ่มเสี่ยงเรื่องปัญหาสุขภาพ ได้แก่ คนอ้วน , มีอายุตั้งแต่ 60 ปีขึ้นไป อีกทั้งเป็นเบาหวานและโรคหัวใจการวิจัยจะแบ่งกลุ่มตัวอย่างเป็น 2 กลุ่ม คือ กลุ่มที่ได้ทานยาจริง กับกลุ่มที่ได้ทานยาหลอก โดยกลุ่มตัวอย่างจะต้องรับประทานยาวันละ 2 เม็ด ผลปรากฏว่า มีเพียงแค่ 7.3%…
Read More
BYD forecasts Q3 profit to almost triple from last year thumbnail

BYD forecasts Q3 profit to almost triple from last year

Chinese EV maker BYD said on Monday that its third-quarter net profit will be more than triple compared to the same period in 2021 at between RMB 5.5 billion and RMB 5.9 billion ($760 million to $820 million), despite a challenging economic situation, Covid-19 rebound, and soaring prices of key components. Such figures would see
Read More
Index Of News
Total
0
Share